248 related articles for article (PubMed ID: 12867221)
1. Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization.
Corrêa JC; Badaró R; Bumroongkit C; Mera JR; Dolmann AL; Juárez Martínez LG; Mayrinck LR; Tamez R; Yang JY
Clin Ther; 2003 May; 25(5):1453-68. PubMed ID: 12867221
[TBL] [Abstract][Full Text] [Related]
2. Clinical and bacteriological outcomes in hospitalised patients with community-acquired pneumonia treated with azithromycin plus ceftriaxone, or ceftriaxone plus clarithromycin or erythromycin: a prospective, randomised, multicentre study.
Tamm M; Todisco T; Feldman C; Garbino J; Blasi F; Hogan P; de Caprariis PJ; Hoepelman IM
Clin Microbiol Infect; 2007 Feb; 13(2):162-171. PubMed ID: 17328728
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia.
Dresser LD; Niederman MS; Paladino JA
Chest; 2001 May; 119(5):1439-48. PubMed ID: 11348951
[TBL] [Abstract][Full Text] [Related]
4. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability.
Lode H; File TM; Mandell L; Ball P; Pypstra R; Thomas M;
Clin Ther; 2002 Nov; 24(11):1915-36. PubMed ID: 12501883
[TBL] [Abstract][Full Text] [Related]
5. A prospective, double-blind, multicenter study comparing clarithromycin extended-release with trovafloxacin in patients with community-acquired pneumonia.
Sokol WN; Sullivan JG; Acampora MD; Busman TA; Notario GF
Clin Ther; 2002 Apr; 24(4):605-15. PubMed ID: 12017405
[TBL] [Abstract][Full Text] [Related]
6. Gatifloxacin in the treatment of community-acquired pneumonias: a comparative trial of ceftriaxone, with or without macrolides, in hospitalized adult patients with mild to moderately severe pneumonia.
Mendonça JS; Yamaguti A; Corrêa JC; Badaró R
Braz J Infect Dis; 2004 Feb; 8(1):90-100. PubMed ID: 15286880
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of once-daily oral telithromycin compared with clarithromycin for the treatment of community-acquired pneumonia in adults.
Mathers Dunbar L; Hassman J; Tellier G
Clin Ther; 2004 Jan; 26(1):48-62. PubMed ID: 14996517
[TBL] [Abstract][Full Text] [Related]
8. Gatifloxacin: a review of its use in the management of bacterial infections.
Perry CM; Ormrod D; Hurst M; Onrust SV
Drugs; 2002; 62(1):169-207. PubMed ID: 11790160
[TBL] [Abstract][Full Text] [Related]
9. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia.
Tellier G; Niederman MS; Nusrat R; Patel M; Lavin B
J Antimicrob Chemother; 2004 Aug; 54(2):515-23. PubMed ID: 15269191
[TBL] [Abstract][Full Text] [Related]
10. Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia.
Bradley JS; Arguedas A; Blumer JL; Sáez-Llorens X; Melkote R; Noel GJ
Pediatr Infect Dis J; 2007 Oct; 26(10):868-78. PubMed ID: 17901791
[TBL] [Abstract][Full Text] [Related]
11. A prospective, randomized, double-blind multicenter comparison of parenteral ertapenem and ceftriaxone for the treatment of hospitalized adults with community-acquired pneumonia.
Vetter N; Cambronero-Hernandez E; Rohlf J; Simon S; Carides A; Oliveria T; Isaacs R;
Clin Ther; 2002 Nov; 24(11):1770-85. PubMed ID: 12501873
[TBL] [Abstract][Full Text] [Related]
12. A controlled, double-blind, multicenter study comparing clarithromycin extended-release tablets and levofloxacin tablets in the treatment of community-acquired pneumonia.
Gotfried MH; Dattani D; Riffer E; Devcich KJ; Busman TA; Notario GF; Palmer RN
Clin Ther; 2002 May; 24(5):736-51. PubMed ID: 12075942
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia.
Hoeffken G; Meyer HP; Winter J; Verhoef L;
Respir Med; 2001 Jul; 95(7):553-64. PubMed ID: 11453311
[TBL] [Abstract][Full Text] [Related]
14. Comparing gatifloxacin and clarithromycin in pneumonia symptom resolution and process of care.
Dean NC; Sperry P; Wikler M; Suchyta MS; Hadlock C
Antimicrob Agents Chemother; 2006 Apr; 50(4):1164-9. PubMed ID: 16569825
[TBL] [Abstract][Full Text] [Related]
15. A prospective, randomized, multicenter comparative study of clinafloxacin versus a ceftriaxone-based regimen in the treatment of hospitalized patients with community-acquired pneumonia.
Petermann W; Alegre-Martin J; Odenholt I; Phillips MJ; Willcox PA; Tack K; Trostmann U; Welling L
Scand J Infect Dis; 2001; 33(11):832-7. PubMed ID: 11760164
[TBL] [Abstract][Full Text] [Related]
16. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment.
Finch R; Schürmann D; Collins O; Kubin R; McGivern J; Bobbaers H; Izquierdo JL; Nikolaides P; Ogundare F; Raz R; Zuck P; Hoeffken G
Antimicrob Agents Chemother; 2002 Jun; 46(6):1746-54. PubMed ID: 12019085
[TBL] [Abstract][Full Text] [Related]
17. Comparison of hospitalization rates in patients with community-acquired pneumonia treated with telithromycin for 5 or 7 days or clarithromycin for 10 days.
Tellier G; Chang JR; Asche CV; Lavin B; Stewart J; Sullivan SD
Curr Med Res Opin; 2004 May; 20(5):739-47. PubMed ID: 15140341
[TBL] [Abstract][Full Text] [Related]
18. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia.
File TM; Segreti J; Dunbar L; Player R; Kohler R; Williams RR; Kojak C; Rubin A
Antimicrob Agents Chemother; 1997 Sep; 41(9):1965-72. PubMed ID: 9303395
[TBL] [Abstract][Full Text] [Related]
19. Comparison of hospitalization rates in patients with community-acquired pneumonia treated with 10 days of telithromycin or clarithromycin.
Niederman MS; Chang JR; Stewart J; Nusrat R; Nieman RB
Curr Med Res Opin; 2004 May; 20(5):749-56. PubMed ID: 15140342
[TBL] [Abstract][Full Text] [Related]
20. A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia.
Frank E; Liu J; Kinasewitz G; Moran GJ; Oross MP; Olson WH; Reichl V; Freitag S; Bahal N; Wiesinger BA; Tennenberg A; Kahn JB
Clin Ther; 2002 Aug; 24(8):1292-308. PubMed ID: 12240780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
